Site Map

Products
Trima Accel® Collection System
How it Works
Automation Benefits
Accessories
User Materials
Spectra Optia Apheresis System
How it Works
Additional Information
Tubing Sets & Accessories
COBE® Spectra Apheresis System
How it Works
What is Therapeutic Apheresis?
What is Cell Therapy?
Accessories
Vista® Information System
How it Works
Regulatory Compliance
Apheresis Management
Elutra® Cell Separation System
How it Works
Monocyte Enrichment
Elutra Publications
Accessories
Atreus® Whole Blood Processing System
How it Works
OrbiSac System
How it Works
Atreus / OrbiSac Synergy
Mirasol® Pathogen Reduction Technology
How it Works
Mirasol Safety and Effectiveness
COBE® 2991 Cell Processor
How it Works
Accessories
Accessories & Supplies
Blood Center
Donor Recruitment and Conversion
Donor Conversion Program
Donor Conversion Materials
Collections Progression
Collections History
Automated Collections
Trima Mobile Collections
Trima Mobiles on the Road
Trima Mobile Collection Guide
Resources
Centers of Excellence
Component Processing Lab
Regulatory Q/A
Information Technology
Therapeutic Apheresis & Cell Therapy Systems
Conditions Treated with Therapeutic Apheresis
Conditions Treated with Cell Therapy
Therapeutic Apheresis Procedures
Cell Therapy Procedures
Blood Products
Platelets
Single-Donor Platelets
Plasma
Red Blood Cells
Buffy Coat Platelets
Whole Blood
Component Safety
Bacterial Testing
Pathogen Reduction Technology
Support Center
SOPs
IFUs
Diagrams
Operator Manuals
Workbooks
Support Materials
ISBT Conversion
Brochures
White Papers
Scientific Literature
Congress Presentations
Tools
Calculation Tools
Links
Educational Events
eSessions
eSessions Presentations
Physician Education
Progressions 2
Successions 2
Program Details
Certificates and Customer Letters
Customer Letters
ACD-A, AS-3 and Disposable Certificates
Contact Us
Email CaridianBCT
Driving Directions
About Us
Global Operations
North America
Latin America
Asia and Pacific
Europe
2006 Releases
Press Release Archive
AABB members contribute over $10,000 to National Blood Foundation
Beauprez visits Gambro campus where federal grants are at work
Navigant Biotechnologies awarded additional USD 2 M Department of Defense research funding
Positive results from clinical trial of platelets treated with Gambro's Mirasol™ Pathogen Reduction Technology
Gambro BCT's blood collection system approved by Japanese Red Cross
Navigant Biotechnologies Awarded $2M Department of Defense Research Funding
Gambro BCT's platelet technology cleared by the US Food and Drug Administration for seven day storage
US FDA clears Gambro BCT’s software for interface with blood center information systems
Navigant Biotechnologies launches website
Gambro BCT and MAK-SYSTEM collaborate to help blood centers optimize automated blood collection
Teresa Ayers appointed President and CEO of Navigant Biotechnologies, Inc., Gambro's subsidiary for Pathogen Reduction Technology
Gambro announces successful research results for inactivation of West Nile Virus in donated blood
Gambro establishes separate company to capture full potential of pathogen reduction technology
Gambro BCT agreement with American Red Cross to supply Trima Automated Blood Collection Technologies
Gambro announces research results for inactivation of malaria in donated blood
Milestone achievement in virus inactivation technology by Gambro to be used in new artificial blood substitute
Gambro BCT receives FDA approval for new red blood cell storage solution
Gambro BCT's Vista™ Software Receives FDA Market Clearance
Gambro BCT receives FDA approval for new anticoagulant solution
Gambro BCT receives FDA clearance for new tubing sets with an integrated red blood cell leukoreduction filter
Hemocentro de São Paulo in Brazil adopts Gambro BCT's Trima® Automated Blood Collection System
Blood Systems Inc. adopts Gambro's Trima System Technology
Dendreon Corporation and Gambro team up for US cell collection network for commercialization of cancer vaccine therapy
Excellent marks from AABB Users' Conference attendees
Gambro's Pathogen Eradication Technology (PET) will be used in the production of Sangart's blood substitute product
Gambro awarded US patent for its unique process of inactivation of pathogens in blood components
Gambro acquires the assets owned by Sanguistech and increases its competitiveness in global blood component technology
Gambro BCT announces research partnership with Walter Reed Army Institute of Research for application of Pathogen Eradication Technology to malaria
Kevin Simpson new Vice President, Gambro BCT and General Manager of its Pathogen Eradication Technology Project
Translation from an entry on the Swedish Reuters screen Monday, January 15, 2001
Gambro BCT announces red blood cell Pathogen Eradication Technology (PET) performance
Gambro BCT Enhances Pathogen Eradication Technology (PET) Performance
What's New
Congresses & Events
2007 Events
Careers
About Our Culture
Benefits & Services
FAQs
Help Save Lives - Join Our Assembly Team